Mitochondrial Non-Coding RNAs for Predicting Disease Progression in Heart Failure and Myocardial Infarction Patients
Institut Pasteur de Lille (Ipl)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,584,383 | Mitochondrial Non-Coding RNAs for Predicting Disease Progression in Heart Failure and Myocardial Infarction Patients Medizinische Hochschule Hannover, Institut National de la Santé et de la Recherche Médicale (Inserm), Université de Lille 2 (Lille 2) - University of Law and Health, Centre Hospitalier Universitaire Lille (Chu) and Institut Pasteur de Lille (Ipl) In force · High confidence UsedRemaining | Medizinische Hochschule Hannover, Institut National de la Santé et de la Recherche Médicale (Inserm), Université de Lille 2 (Lille 2) - University of Law and Health, Centre Hospitalier Universitaire Lille (Chu) and Institut Pasteur de Lille (Ipl) | In force | High confidence |
1 of 1 record shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.